Biomea Fusion Inc., a clinical-stage company specializing in diabetes and obesity, has announced a public offering of its common stock and accompanying warrants. The offering includes shares, pre-funded warrants, and common stock warrants, all to be sold by Biomea. The company has also provided underwriters with a 30-day option to purchase an additional 15% of the shares and pre-funded warrants. The offering is being conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission. Jefferies is serving as the sole book-running manager for this offering, which is expected to close around June 20, 2025, subject to customary conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.